Cohance Lifesciences Limited has announced a meeting of its Board of Directors to be held on February 12, 2026. The primary agenda of the meeting is to review and approve the unaudited financial results for the quarter and nine-month period ending December 31, 2025. The company also announced the closure of the trading window from January 1, 2026, to February 14, 2026.
Board Meeting Announcement
The Board of Directors of Cohance Lifesciences Limited is scheduled to convene a meeting on February 12, 2026. The purpose of this meeting is to consider and approve the unaudited financial results of the company.
Financial Results on the Agenda
During the upcoming board meeting, the directors will review the unaudited financial performance of Cohance Lifesciences Limited. The review period will encompass the financial results for the quarter and nine-month period concluding on December 31, 2025.
Trading Window Closure
In compliance with insider trading regulations, Cohance Lifesciences Limited has announced the closure of its trading window for dealing in the company’s securities. This restriction will be in effect from January 1, 2026, and will continue until February 14, 2026. This measure ensures fairness and prevents any potential misuse of unpublished price-sensitive information during the results finalization period.
Source: BSE
